Pediatric Antiviral Treatment for Influenza B

Introduction to Oseltamivir Treatment

The American Academy of Pediatrics recommends oral oseltamivir (Tamiflu) suspension at 6 mg/mL concentration as the antiviral drug of choice for treating influenza B in pediatric patients, with weight-based dosing administered twice daily for 5 days 1, 2

Oseltamivir demonstrates effectiveness against influenza B, though the response may be slightly less robust than for influenza A 1, 2
The American Academy of Pediatrics indicates immediate treatment for all hospitalized children with suspected or confirmed influenza B, children with severe or complicated illness, and children at high risk for complications 1, 6

The greatest clinical benefit occurs when treatment begins within 12-36 hours of symptom onset 3
Treatment should be initiated empirically without waiting for laboratory confirmation in high-risk groups 6, 3
Oseltamivir should be administered twice daily for 5 days, without regard to meals, though administration with food improves gastrointestinal tolerability 5, 4

Inhaled zanamivir (Relenza) is an acceptable alternative for children ≥7 years without chronic respiratory disease, but is more difficult to administer 1, 2, 7
Intravenous peramivir is FDA-approved only for acute uncomplicated influenza in non-hospitalized children ≥6 months who have been symptomatic ≤2 days 1, 7, 8
Critical pitfalls to avoid include delaying treatment while waiting for laboratory confirmation, relying on negative rapid antigen tests, withholding treatment beyond 48 hours, and using amantadine or rimantadine 6, 8, 5, 4, 7, 3

The American Academy of Pediatrics recommends considering oseltamivir treatment for any healthy child with presumed influenza, especially for those with household contacts at high risk for complications, such as young siblings or household members with medical conditions 9
Children under 5 years are at increased risk for influenza complications and hospitalizations, making oseltamivir treatment a priority 9
Household contact with confirmed influenza A increases the likelihood of influenza diagnosis, despite atypical presentations such as a "croupy" cough 9

The American Academy of Pediatrics explicitly recommends initiating oseltamivir treatment immediately without waiting for laboratory confirmation in high-risk scenarios, such as household exposure to confirmed influenza A 9

Oseltamivir treatment initiated within 12-36 hours of symptom onset reduces illness duration by approximately 1.5 days (26-36 hours) 9
Treatment with oseltamivir reduces the risk of secondary otitis media by 44% (12% vs 21% in placebo) 9
Oseltamivir treatment reduces antibiotic prescriptions by 31% compared to 41% in untreated children 9

The most common adverse effect of oseltamivir is vomiting (15% with oseltamivir vs 9% with placebo), which is typically mild and transient 9

Close monitoring is warranted in young children with confirmed household exposure to influenza A, with attention to adequate voiding, appropriate color, and reasonable appetite 9